Search Results for “EC” – Page 49 – media

New digital iTalkBetter app significantly improves speech in stroke patients

Aphasia is a language disorder caused by some form of brain damage, including stroke Researchers from the Neurotherapeutics Group at University College London’s Queen Square Institute of Neurology have developed a new digital app that significantly improves speech in stroke patients. Supported by Wellcome and funded by the National Institute for Health and Care Research (NIHR), the iTalkBetter app provides speech therapy for people living with aphasia, a language disorder. Caused by some form of brain damage, including stroke, severe head injury and brain tumours, aphasia can lead to difficulties with speech or language. The NHS currently provides around 12 hours of speech and language therapy, with further face-to-face therapy available via some charities or privately. However, most aphasia patients are undertreated with therapy. The new app offers practice for over 200 commonly used words, games to maintain engagement and an integrated speech recogniser to analyse speech in real time ...
- Source: drugdu
- 90
- March 2, 2024
Henlius Adalimumab Biosimilar Received sNDA Acceptance Notification from the NMPA

Shanghai, China, 29th February 2024 – Shanghai Henlius Biotech, Inc. (2696.HK) announced that the supplemental new drug applications (sNDAs) of its adalimumab biosimilar HANDAYUAN for the treatment of polyarticular juvenile idiopathic arthritis，pediatric plaque psoriasis and other indications have been accepted by the National Medical Products Administration (NMPA)，bringing new hope to pediatric patients and their families. As of now, HANDAYUAN has been approved for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis and uveitis. Autoimmune diseases are a group of diseases caused by the body’s immune system attacking its own organs or tissues. It is estimated that approximately 7.6%-9.4% of the global population suffers from various types of autoimmune diseases. Currently, autoimmune diseases are difficult to cure, and once it occurs, most patients need long-term to lifelong medication. Some autoimmune diseases are particularly dangerous and severely affect the quality of life of patients, posing a threat to their lives and ...
- Source: drugdu
- 136
- March 2, 2024
The marketing application for new indications of Anrotinib hydrochloride capsule and anti-PD-L1 “Behmosubaisumab (TQB2450 injection)” of Zhengda Tianqing has been accepted.

Recently, Anrotinib Hydrochloride Capsules and anti-PD-L1 “Behmosubaisumab (TQB2450 Injection)” developed by Zhengda Tianqing have submitted a new indication application to the Center for Drug Evaluation of the State Drug Administration (CDE), which has been accepted, with the indications of non-microsatellite patients who have previously failed to receive or cannot tolerate the first- or second-line chemotherapy regimens. Recurrent or metastatic endometrial cancer that is not microsatellite highly unstable (non-MSI-H) or non-DNA mismatch repair defective (non-dMMR), or intolerant. Bemosumab is an innovative, fully humanized anti-PD-L1 monoclonal antibody with a new sequence developed by AstraZeneca.In April 2022, Bemosumab in combination with amrutinib hydrochloride capsules for the treatment of recurrent or metastatic endometrial cancer was included in the Breakthrough Therapeutic Classification by the CDE.In January 2023, Bemosumab’s application for marketing in the first-line treatment of recurrent or metastatic endometrial cancer in combination with amrutinib hydrochloride capsules was formally accepted by the CDE.The application was ...
- Source: drugdu
- 142
- March 2, 2024
AstraZeneca’s “CD19/CD3 dual antibody” receives clinical approval in China

According to the CDE official website, AstraZeneca’s Class 1 therapeutic biological product AZD0486 has obtained implicit approval for clinical trials and is intended to be used to treat relapsed or refractory B-cell acute lymphoblastic leukemia. AZD0486 (TNB-486) is a new, fully human CD19xCD3 IgG4 bispecific antibody, originally developed by TeneoTwo. In 2022, AstraZeneca acquired TeneoTwo for US$1.265 billion and also obtained its clinical-stage drug TNB-486. According to public information, AZD0486 can bind to CD19 on the surface of B lymphocytes and CD3 receptors on the surface of T lymphocytes, thereby initiating the immune response of T lymphocytes. A Phase I clinical study (NCT04594642) published in the journal “OncLive” in August 2023 showed that AZD0486 has a durable tumor inhibitory effect on relapsed/refractory follicular lymphoma, regardless of the expression level of CD20, and it is also independent of the type and dosage of existing drugs. Currently, AZD0486 has entered the Phase ...
- Source: drugdu
- 92
- March 2, 2024
Pharmtech Ingredients 2024

Organiser: ITE Time:19 – 21 November 2024 address：Crocus Expo IEC, Krasnogorsk, 65 -66 km Moscow RingRoad ,Russia Exhibition hall: Crocus- Expo IEC Product range: Pharmaceutical machinery: preparation production equipment, pharmaceutical water equipment, equipment, Chinese medicine treatment equipment, refrigeration equipment, etc Packaging equipment materials: aluminum plastic packaging machine, filling machine, tablet machine, labeling machine, inkjet machine, anti-counterfeiting printing and packaging production line, bar code composite technology equipment, self-adhesive printing and packaging equipment, plastic packaging products, packaging container filling and sealing machine, packaging machine, bag packaging machine, multi-functional bottle packaging machine, glass packaging products and medicinal packaging materials production facilities standby Laboratory equipment/Analytical testing: laboratory equipment and devices, laboratory consumables, chemical reagents, biochemical/analytical instruments, biotechnology analytical testing instruments, pharmaceutical testing equipment, food analytical testing instruments, pharmaceutical industry analytical instruments, etc Fluid equipment: sanitary pumps, valves, fluid engineering, pipes and fittings, microfiltration, ultrafiltration, etc Clean system: clean air conditioning equipment, clean studio/desk, clean equipment, ...
- Source: drugdu
- 179
- March 1, 2024
World’s First Low-Cost, High-Throughput, Near-Patient Molecular Diagnostic Test System Dramatically Reduces Wait Times

It is important for doctors to rapidly and accurately identify prevalent respiratory pathogens like COVID-19, influenza A and B, RSV-A, and RSV-B for administering prompt, tailored treatment to infected individuals. In a significant advancement, a near-patient test system using automation technology detects pathogens with unrivaled speed and cuts the typical waiting time of 24 to 48 hours to just one to two hours without the need for expensive biosafe laboratories. Fast MDx Limited (Middlesex, UK) and Festo (London, UK) have jointly designed and developed the world’s first, low-cost, high-throughput, near-patient molecular diagnostic test system that will provide clinicians with earlier, more informed results, allowing each patient to receive a faster, personalized clinical pathway. The Fast MDx system comprises everything necessary for testing, including sample tubes, swabs, and even electronic result transmission to the originating hospital, clinic, or doctor’s office. The system incorporates Fast MDx’s latest, ultra-fast, NGx2 4-Channel qPCR thermal ...
- Source: drugdu
- 107
- February 29, 2024
Allecra Therapeutics’ Exblifep Approved by FDA for Complicated Urinary Tract Infections

Davy James The FDA granted Allecra with a five-year marketing exclusivity extension for Exblifep (cefepime/enmetazobactam) through the Generating Antibiotic Incentives Now Act. The FDA has approved Allecra Therapeutics’ Exblifep (cefepime/enmetazobactam) for the treatment of complicated urinary tract infections (cUTIs), including the kidney infection pyelonephritis, in patients aged 18 years and older.1 The FDA also granted Allecra with a five-year marketing exclusivity extension for the β-lactam/β-lactamase inhibitor combination through the Generating Antibiotic Incentives Now Act (GAIN Act), which is legislation that incentivizes the development of new anti-infective treatments. “Receiving FDA approval is a tremendous achievement for Allecra and a testament to the hard work and dedication of a small, yet highly focused team of individuals. I extend my sincere congratulations to my colleagues Omar Lahlou and Patrick Velicitat for their leadership and oversight throughout this whole process,” Iain Buchanan, supervisory board member of Allecra Therapeutics, said in a press release. “As ...
- Source: drugdu
- 115
- February 29, 2024
New Blood Testing Method Detects Potent Opioids in Under Three Minutes

Fentanyl, an opioid 50 times more potent than heroin, presents a major risk to public health. In recent years, there’s been a growing concern over the rise in fentanyl use among drug users. Annually, this potent drug is responsible for thousands of overdose deaths globally. In response to this crisis, a breakthrough in drug testing has been achieved. Now, researchers have developed a new blood testing method capable of detecting powerful opioids, including fentanyl, more rapidly than traditional methods, thereby offering a potential lifeline in overdose situations. This innovative method developed by a team at the University of Waterloo (Ontario, Canada) can simultaneously analyze up to 96 blood samples for the presence of opioids like fentanyl in less than three minutes, a rate that’s double the speed of existing methods. To conduct the test, a small volume of blood is placed into each well of a 96-well plate, which also ...
- Source: drugdu
- 117
- February 28, 2024
Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season

The World Health Organization (WHO) today announced the recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The announcement was made at an information session after a 4-day meeting on the Composition of Influenza Virus Vaccines. The meeting is held twice annually, once for the southern and once for the northern hemisphere. WHO organizes these consultations with an advisory group of experts gathered from WHO Collaborating Centres and WHO Essential Regulatory Laboratories to analyse influenza virus surveillance data generated by the WHO Global Influenza Surveillance and Response System (GISRS). The recommendations issued are used by the national vaccine regulatory agencies and pharmaceutical companies to develop, produce, and license influenza vaccines for the following influenza season. The periodic update of viruses contained in influenza vaccines is necessary for the vaccines to be effective due to the constant evolving nature of influenza viruses, including ...
- Source: drugdu
- 80
- February 28, 2024
PhaSER Biomedical receives $2.3m drug discovery grant from the Gates Foundation

Every year, tuberculosis, malaria and HIV cause over five million deaths worldwide PhaSER Biomedical has received a grant from the Bill & Melinda Gates Foundation worth $2.3m to accelerate drug discovery and development. PhaSER’s technology, 8HUM, will become a collaborating institution within the Global Health Discovery Collaboratory Programme, funded by the Gates Foundation. As part of the three-year programme, PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in the metabolism and disposition of drugs, to all grantees of the foundation. Collaborating researchers involved in combating diseases including malaria, tuberculosis (TB), HIV, pandemic preparedness and non-hormonal contraception will be provided with access to the drug discovery and development platform. Considered the ‘big three’ infectious diseases, TB, malaria and HIV are responsible for more than five million deaths worldwide every year. Formed in 2022 in collaboration with researchers at the University of Dundee, CXR Biosciences, Taconic Farms and ...
- Source: drugdu
- 133
- February 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.